Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration

• Published in: Graefe's archive for clinical and experimental ophthalmology Vol. 252; no. 7; pp. 1033 - 1039
• Main Authors: Wang, Xiying, Sawada, Tomoko, Kakinoki, Masashi, Miyake, Taichiro, Kawamura, Hajime, Saishin, Yoshitsugu, Liu, Ping, Ohji, Masahito
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2014; Springer Nature B.V
• Subjects: Aged; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - pharmacokinetics; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacokinetics; Aqueous Humor - metabolism; Biological Availability; Enzyme-Linked Immunosorbent Assay; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Macular degeneration; Male; Medicine; Medicine & Public Health; Middle Aged; Ophthalmology; Pilot Projects; Ranibizumab; Retinal Disorders; Tissue Distribution; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Vascular Endothelial Growth Factor A - metabolism; Visual Acuity - physiology; Wet Macular Degeneration - drug therapy; Wet Macular Degeneration - metabolism; Aqueous humor; Bimonthly intravitreal injection; Age-related macular degeneration; Vascular endothelial growth factor; Ranibizumab

Purpose To evaluate vascular endothelial growth factor (VEGF) and ranibizumab concentrations in eyes with age-related macular degeneration (AMD) after monthly and bimonthly intravitreal ranibizumab (IVR) injections. Methods Aqueous humor samples were obtained from 26 eyes with AMD before and after I...